Company / Revenue
Mirum Pharmaceuticals, Inc. Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$521.3M
FY2025
5-year range
$0 / $521.3M
FY2021-FY2025
Trend
+54.7%
vs FY2024
Sector context
#63 of 155
Health Care
What the data says
At $521M, Mirum Pharmaceuticals, Inc.'s revenue ranks #63 of 155 in the Health Care sector. Revenue has increased for 4 consecutive years, from $0 in FY2021 to $521M in FY2025.
Based on SEC 10-K filings.
$521M in FY2025 with a 3-year CAGR of +200.9%.
Improved from $186M to $521M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +200.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#63 of 155 in Health CareTop 41% of 155This company $521.3M Sector average $4.5B
▼
-88.3% below sector average
Key checks
Key Insights
- Mirum Pharmaceuticals, Inc.'s revenue has grown for 3 consecutive years.
- 3-year CAGR of +200.9%, indicating consistent growth.
- In FY2025, revenue increased 54.7% year-over-year.
- Ranks #63 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $521.3M | +54.7% |
| FY2024 | $336.9M | +80.8% |
| FY2023 | $186.4M | +873.8% |
| FY2022 | $19.1M | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026